Roche is the world’s top oncology company by sales, earning nearly US$28 billion in 2018 just from its anticancer drugs. And oncologist Sandra Horning has been instrumental in making that possible, shaping the company’s development priorities for the past decade. An oncologist by training, Horning served as Global Head of Clinical Science for Oncology and Hematology at Genentech/Roche from 2009 to 2014, and then as Chief Medical Officer and Head of Global Product Development at the company from 2014 to 2019. In December she retired from this role. She spoke with Asher Mullard about how she has thought about Roche’s cancer pipeline, real-world evidence and more.